Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMAL: PEGPH20 + Docetaxel in NSCLC
NCT02346370Phase 1Terminated
- Sponsor
- Halozyme Therapeutics, Inc.
- Start
- Feb 2015
- Primary completion
- Aug 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pegvorhyaluronidase alfa in non-small cell lung cancer (NSCLC), sponsored by Halozyme Therapeutics, Inc. Primary endpoints: Dose Limiting Toxicities, Adverse Events and 1 more. Started Feb 2015; status: terminated.
02
Drugs
pegvorhyaluronidase alfa
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02346370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02346370.